CG Oncology CGON Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $33.7M-18.7% | $32.49M-87.4% | $45.15M+4.0% | $14.62M— | $41.47M— | ||
| $1.04B+61.1% | $709.67M+46.3% | $635.12M+27.7% | $646.43M— | $646.96M— | ||
| $1.28M+270% | $688K-11.9% | $515K+276% | $562K— | $345K— | ||
| —— | —— | —— | —— | —— | ||
| $1.1B+57.2% | $759.48M+0.7% | $695.79M+26.0% | $673.03M— | $701.19M— | ||
| $15.07M+5,610% | $15.6M+5,634% | $15.33M+24,232% | $253K— | $264K— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $1.14B+55.9% | $791.59M+4.9% | $729.91M+32.1% | $701.45M— | $728.18M— | ||
| $30.27M+38.7% | $28.76M+45.7% | $29.57M+79.5% | $24.45M+88.3% | $21.82M+155% | ||
| $35.22M+55.5% | $30.84M+44.3% | $30.53M+95.3% | $30.38M— | $22.64M— | ||
| —— | —— | —— | —— | —— | ||
| $43.48M+85.6% | $38.99M+82.0% | $42.27M+169% | $31.09M— | $23.42M— | ||
| $9K+12.5% | $8K0.0% | $8K— | $8K— | $8K— | ||
| -$439.18M-74.0% | -$378.98M-73.9% | -$337.67M-81.4% | -$293.86M— | -$252.43M— | ||
| $1.09B+54.9% | $752.6M+2.6% | $687.64M+28.1% | $670.36M+21.4% | $704.76M+23.9% | ||
| $1.14B+55.9% | $791.59M+4.9% | $729.91M+32.1% | $701.45M— | $728.18M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can CG Oncology cover its short-term obligations?
- Its current ratio is 31.30 — current assets exceed current liabilities.
- Where does CG Oncology's balance sheet data come from?
- Every line is extracted from CG Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.